Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2019 | GEM-Claridex: C-Rd for transplant ineligible NDMM

Noemí Puig, MD, PhD, University Hospital of Salamanca, Salamanca, Spain, discusses the results from GEM-Claridex (NCT02575144). This open, randomized, phase 3 trial investigated the addition of clarithromycin to lenalidomide and dexamethasone (C-Rd) in patients with untreated newly diagnosed multiple myeloma ineligible for autologous stem cell transplantation. This addition significantly increased the rate and depth of response, but ultimately this did not translate to an improved PFS and OS due to a higher proportion of deaths, which were mostly infectious. Dr Puig highlights how C-Rd could potentially be used in the younger population with the addition of infectious prophylaxis. This interview took place at the American Society of Hematology (ASH) 2019 Annual Meeting and Exposition in Orlando, FL.